Jon Congleton - 19 Feb 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MLYS
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 19:47:45 UTC
Prior SEC filing: 13 Jan 2026
Next SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Jon Congleton filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 20 Feb 2026.

Key facts

This page summarizes Jon Congleton's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 19:47.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644975 Primary reporting owner

Congleton Jon

Relationship: Chief Executive Officer, Director
Address: 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Award

Transaction value: $0
Shares: +140,900
Change %: +22%
Price: $0.000000
Shares after: 780,051
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +187,900
Change %
Price: $0.000000
Shares after: 187,900
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 187,900
Exercise price: $28.06
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.

Footnote F2

The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant